In a filing, Harmony Biosciences Holdings Inc revealed its Officer JEFFREY G DIERKS acquired Company’s shares for reported $0.53 million on Oct 03 ’24. In the deal valued at $35.57 per share,14,961 shares were bought.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Dierks Jeffrey sold 400 shares, generating $16,077 in total proceeds. Upon selling the shares at $40.19, the CHIEF COMMERCIAL OFFICER now owns 0 shares.
Before that, JEFFREY G DIERKS bought 21,796 shares. Harmony Biosciences Holdings Inc shares valued at $871,840 were divested by the Officer at a price of $40.00 per share.
UBS initiated its Harmony Biosciences Holdings Inc [HRMY] rating to a Buy in a research note published on September 10, 2024; the price target was $56. A number of analysts have revised their coverage, including Citigroup’s analysts, who began to cover the stock in late June with a ‘”a Buy”‘ rating. BofA Securities also remained covering HRMY and has decreased its forecast on January 02, 2024 with a “an Underperform” recommendation from previously “Neutral” rating. Goldman revised its rating on September 25, 2023. It rated HRMY as “a Sell” which previously was an “a Neutral”.
Price Performance Review of HRMY
On Tuesday, Harmony Biosciences Holdings Inc [NASDAQ:HRMY] saw its stock jump 1.08% to $34.75. Over the last five days, the stock has lost -11.44%. Harmony Biosciences Holdings Inc shares have risen nearly 7.59% since the year began. Nevertheless, the stocks have risen 7.22% over the past one year. While a 52-week high of $40.60 was reached on 10/01/24, a 52-week low of $18.61 was recorded on 04/25/24. SMA at 50 days reached $36.06, while 200 days put it at $32.55.
Levels Of Support And Resistance For HRMY Stock
The 24-hour chart illustrates a support level at 34.08, which if violated will result in even more drops to 33.42. On the upside, there is a resistance level at 35.16. A further resistance level may holdings at 35.58. The Relative Strength Index (RSI) on the 14-day chart is 40.03, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -2.84, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 81.02%. Stochastics %K at 12.88% indicates the stock is a buying.
How much short interest is there in Harmony Biosciences Holdings Inc?
A steep rise in short interest was recorded in Harmony Biosciences Holdings Inc stocks on 2024-09-13, dropping by -0.31 million shares to a total of 8.41 million shares. Yahoo Finance data shows the prior-month short interest on 2024-08-15 was 8.73 million shares. There was a decline of -3.73%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on September 07, 2023 when Berenberg began covering the stock and recommended ‘”a Buy”‘ rating along with a $59 price target.
